Fierce Drug Dev Forum 2019 has ended
avatar for Sabah Oney, Ph.D

Sabah Oney, Ph.D

Chief Business Officer
Sabah Oney, PhD, is Chief Business Officer at Alector, a clinical stage biotechnology company leveraging the immune system to cure neurodegeneration.

Sabah joined Alector in 2016 and has been leading the company's fundraising, partnering, business development, finance, PR, and IT activities. Sabah executed Alector's $188M IPO at $1.3 billion valuation as well as its previous $133 million mezzanine fundraise and ongoing $1.3 billion partnership with AbbVie.

Prior to joining Alector, Sabah was the head of global sales and business development at Ariosa Diagnostics, Inc. through its acquisition by Roche Holding AG, where he led a team that negotiated and executed over 100 partnering deals globally.
Sabah received his PhD in Genetics and Genomics from Duke University, his MBA from Stanford Graduate School of Business, and his BS in Genetics from the University of Kansas.

My Speakers Sessions

Monday, October 28

3:15pm PDT